Newsroom

News

Experts are increasingly turning to machine learning to predict antibiotic resistance in pathogens. With its help, resistance mechanisms can be identified based on a pathogen’s genetics. However, the results should be viewed with caution: Researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg have shown that the models are often less reliable than assumed. Their findings were published in the journal PLOS Biology. They contribute to the development of more reliable tools for predicting and combating antibiotic resistance.

17.12.2025

HIRI

Teaser for the podcast with Andreas Keller

News

At first glance, biology and computer science seem like opposites. But wherever enormous amounts of data are generated from research, progress is hardly possible without digital methods. Bioinformatician Prof. Andreas Keller therefore relies on artificial intelligence. He heads the department “Clinical Bioinformatics” at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS). In this episode of InFact, he talks about how AI can help us understand how beneficial and harmful bacteria communicate with each other in our bodies, how to predict when infections will cause long-term effects, and how this can be used to develop new drugs against dangerous pathogens.

16.12.2025

HIPS

News

Biphenomycins, natural products derived from bacteria, show excellent antimicrobial activity, but have long remained out of reach for drug development. The main obstacle was the limited understanding of how these compounds are produced by their microbial hosts. A research team led by Tobias Gulder, department head at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), has now deciphered the biosynthetic pathway of the biphenomycins, establishing the foundation for their pharmaceutical advancement. The team published its findings in the journal Angewandte Chemie International Edition.

11.12.2025

HIPS

Maximilian Order awarded to HIRI Director Jörg Vogel by Marcus Söder

News

On December 3, Jörg Vogel, Director of the Helmholtz Institute for RNA-based Infection Research, was honored with the Maximilian Order for Science and Art at a ceremony held in the Antiquarium of the Munich Residence. He received the distinction from Bavarian Minister-President Markus Söder, who referred to the Free State’s highest honor as the ‘Bavarian Nobel Prize’. HIRI is site of the Braunschweig Helmholtz Centre for Infection Research (HZI) in cooperation with the Julius-Maximilians-Universität Würzburg (JMU).

04.12.2025

HIRI

Group photo with 11 people behind a 3D lettering “HZI 60”

News

On November 27, 2025, the Helmholtz Centre for Infection Research (HZI) celebrated its 60th anniversary with a ceremony attended by cooperation partners, alumni, and guests from the worlds of science, politics, and industry. The research institution has been located on the Science Campus Braunschweig-Süd since 1965 and underwent several reorientations and renaming in the following decades. Among those offering their congratulations at the ceremony were Lower Saxony's Minister President Olaf Lies, the new President of the Helmholtz Association Prof. Martin Keller, and his predecessor and long-time companion of the HZI, Prof. Otmar D. Wiestler.

27.11.2025

HZI Campus

Crystal structure of LecA and tolcapone.

News

When the hospital germ Pseudomonas aeruginosa infects the body, it uses the sugar-binding protein LecA to attach itself to human cells, invade them, and form so-called biofilms. LecA thus plays a central role in the development and progression of infections with this pathogen, which is classified as particularly critical by the WHO. Researchers at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) have now discovered that the approved Parkinson's drug tolcapone is able to specifically inhibit the activity of LecA. This finding allows the research team to develop new strategies for combating Pseudomonas infections. The researchers published their findings in the journal Angewandte Chemie International Edition.

26.11.2025

HIPS

HZI in the media

Biosyntheseweg aufzuklären. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung (HZI) in Zusammenarbeit mit ...

18.12.2025

Bionity.COM

Forschende vom Würzburger Helmholtz-Institut für RNA-basierte Infektionsforschung (HIRI), einem Standort des Braunschweiger Helmholtz- ...

17.12.2025

Verband Deutscher Biologen e.V.

Finanzierungsmöglichkeiten fehlen.

Josef Penninger, wissenschaftlicher Geschäftsführer des Helmholtz-Zentrums für Infektionsforschung (HZI)

16.12.2025

MedMedia

Korte from the Technical University of Braunschweig and the Helmholtz Centre for Infection Research (HZI).

The research was carried out as

12.12.2025

The Hindu

... des Leibniz Lungenzentrums Borstel, des Helmholtz-Instituts für Pharmazeutische Forschung Saarland sowie weiterer wissenschaftlicher ...

12.12.2025

Bionity.COM

Einrichtungen des regionalen Forschungsökosystems – darunter das Helmholtz-Zentrum für Infektionsforschung (HZI), das Deutsche Zentrum für

12.12.2025

EUROPE SAYS

Korte of the Technical University of Braunschweig and the Helmholtz Centre for Infection Research (HZI). The findings emerged from the

12.12.2025

The New Indian Express

Universität Würzburg. Seit 2018: Postdoc am Helmholtz-Institut für RNA-basierte Infektionsforschung (HIRI), Entwicklung Bayes’scher ...

12.12.2025

BIOspektrum

Center Borstel - Leibniz Lung Center, the Helmholtz Institute for Pharmaceutical Research Saarland and other scientific institutions in

11.12.2025

Technology Networks

von Humboldt professor, head of department at the Helmholtz Centre for Infection Research, Braunschweig and full professor at the Hannover

10.12.2025

European Research Council

... so Prof. Dr. Berit Lange, Leiterin der Abteilung für Epidemiologie am Helmholtz-Zentrum für Infektionsforschung sowie ...

10.12.2025

Apotheken Umschau

Quelle:

Pressemitteilung Helmholtz-Zentrum für Infektionsforschung HZI ...

10.12.2025

LaborPraxis

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.